טוען...

Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors

PURPOSE: Combining cytotoxic agents with bevacizumab has yielded significant benefits in a number of solid tumors. Combining small-molecule kinase inhibitors of VEGFR with chemotherapy has yet to demonstrate clinical benefit. The dose, schedule and agents used may be critical to the development of t...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Brell, Joanna M., Krishnamurthi, Smitha S., Rath, Linda, Bokar, Joseph A., Savvides, Panayiotis, Gibbons, Joseph, Cooney, Matthew M., Meropol, Neal J., Ivy, Percy, Dowlati, Afshin
פורמט: Artigo
שפה:Inglês
יצא לאור: 2012
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4199746/
https://ncbi.nlm.nih.gov/pubmed/22868341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1936-5
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!